# Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

- Link: https://www.thailand-business-news.com/pr-news/harbour-biomed-appoints-dr-dhavalkumar-patel-as-scientific-advisor
- Published: 2026-06-12T08:19:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 12, 2026 /PRNewswire/—
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company 
committed to the discovery and development of novel antibody therapeutics in immunology,
oncology and other disease areas, today announced the appointment of Dr. Dhavalkumar
Patel as Scientific Advisor.

Dr. Patel brings an outstanding track record of therapeutic innovation spanning 
over two decades in industry and academia. He is currently Executive Vice President
and Chief Scientific Officer of Sana Biotechnology.

Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice 
President and Chief Scientific Officer of UCB, where he and his teams contributed
to the registration of bimekizumab (Bimzelx^(®)), rozanolixizumab (Rystiggo^(®))
and zilucoplan (Zilbrysq^(®)). Prior to UCB, he spent 10 years at Novartis, most
recently as the Head of Research of the Novartis Institutes for BioMedical Research(
NIBR) Europe. During his tenure, he led research in the autoimmune, transplantation,
and inflammation disease areas, contributing to the registration of secukinumab (
Cosentyx^(®)), fingolimod (Gilenya^(®)), siponimod (Mayzent^(®)), canakinumab (Ilaris
^(®)), everolimus (Zortress^(®)/Certican^(®), Afinitor^(®)), leniolisib (Joenja^(
®)), and iptacopan (Fabhalta^(®)) in multiple indications. He was also an Entrepreneur
in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board
of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently
serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM 
Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV.

Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine,
Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston
Arthritis Research Center at the University of North Carolina in Chapel Hill. He
also spent nine years at the Duke University School of Medicine, culminating in 
his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received
his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and
is board certified in internal medicine, rheumatology, and allergy & immunology.

"We are thrilled to welcome Dr. Patel to our Scientific Advisory Board," said Dr.
Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. "His outstanding combination
of deep immunological science, proven drug development success, and board-level 
strategic insight will be a tremendous asset to us. We look forward to his guidance
as we continue to build a leading immunology pipeline."

"I am honored to join Harbour BioMed as a Scientific Advisor," said Dr. Dhavalkumar
Patel. "Harbour BioMed has built a compelling portfolio of novel antibody candidates
targeting key immune pathways, and I believe the company is well-positioned to make
meaningful progress in areas of high unmet medical need. I look forward to working
closely with the team to help advance these programs from discovery through development
and ultimately to patients."

**About Harbour BioMed**

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to 
the discovery and development of novel antibody therapeutics in immunology, oncology
and other areas. The Company is building a robust portfolio and differentiated pipeline
through internal R&D capability, strategic global collaborations in co-discovery
and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice^(®), generates fully 
human monoclonal antibodies in both the conventional two heavy and two light chain(
H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies,
the HCAb-based immune cell engagers (HBICE^(®)) bispecific antibody technology enables
tumor-killing effects that traditional combination therapies cannot achieve. The
HCAb-based Antibody Plus technology (HCAb PLUS^(TM)) provides comprehensive modality
solutions for the development of innovative multi-specific medicines in different
disease areas. Additionally, building upon the Harbour Mice^(®) platform, Harbour
BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-
mAtrIx^(TM) AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice^(®), HBICE^(®), HCAb PLUS^(TM), a single B-cell cloning
platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive
antibody discovery engine for developing next-generation therapeutic antibodies.
For more information, please visit [www.harbourbiomed.com](https://www.harbourbiomed.com/).

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor ](http://www.prnasia.com/story/archive/4982280_CN82280_0?rand=184833)